You are here


02 - 03 - 2017

A new lead to tackle triple negative breast cancer

Triple negative breast cancer accounts for about 20% of breast tumours. Aggressive and difficult to treat, it is not sensitive to targeted therapies and often resists chemotherapy.

However, researchers have just discovered a weak spot : under chemotherapy, the tumour cells begin to produce a lot of pyrimidine, for an unknown reason. This was shown in vitro and in vivo in mice models.

In vitro or in vivo, if an inhibitor of pyrimidine synthesis, leflunomide, is added to the chemotherapy mix, cancer regresses. Since leflunomide is already used in the treatment of rheumatoid arthritis, a clinical trial could be scheduled rapidely.